U.S., June 25 -- ClinicalTrials.gov registry received information related to the study (NCT07034053) titled 'Clofarabine Therapy in Locally Advanced or Metastatic Urothelial Carcinoma' on June 04.
Brief Summary: This phase 1/2 study will evaluate the maximum tolerated dose, efficacy, and safety of clofarabine in patients with advanced or metastatic urothelial cancer.
Study Start Date: Oct. 24, 2023
Study Type: INTERVENTIONAL
Condition:
Advanced Urothelial Carcinoma
Metastatic Urothelial Cancer
Intervention:
DRUG: Clofarabine
Patients receive i.v. clofarabine in a dose-escalation regimen
Recruitment Status: RECRUITING
Sponsor: Ekaterina Laukhtina
Information provided by (Responsible Party): Ekaterina Laukhtina, Medical University ...